Inc. ("Exicure" or the "Company") (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on April 17, 2024 notifying the Company that ...

The firm has a market cap of $22.03 million, a price-to-earnings ratio of -4.08 and a beta of 3.76. An institutional investor recently bought a new position in Exicure stock. Geode Capital ...

More about Exicure YTD Price Performance:-5.40% Average Trading Volume: 757,793 Technical Sentiment Consensus Rating: Sell Current Market Cap: $37.42M For an in-depth examination of XCUR stock ...

Exicure (XCUR) “announced that on January 19, 2025, Exicure Inc. entered into a Share Purchase Agreement with GPCR Therapeutics Inc., a Korean corporation, pursuant to which the Company acquired ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

(RTTNews) - Exicure, Inc. (XCUR), a biotechnology company, has announced the signing of a Memorandum of Understanding (MOU) with GPCR Therapeutics, Inc., marking a major step in advancing its ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Company is diligently working to timely satisfy the terms of the Panel’s requests and to ensu CHICAGO, August 26, 2024--Exicure, Inc. (Nasdaq: XCUR, "the Company") today announced that it will ...

Inc. ("Exicure" or the "Company") (Nasdaq: XCUR), announced today it received notice of a delisting determination (the "Staff Delisting Determination") from the Listing Qualifications Department of ...